Biodesix, Inc. BDSX Diagnostic Tests — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biodesix, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biodesix, Inc.'s diagnostic tests — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biodesix, Inc.'s diagnostic tests — revenue?
- Biodesix, Inc. (BDSX) reported diagnostic tests — revenue of $22.29M in Q1 2026.
- How has Biodesix, Inc.'s diagnostic tests — revenue changed year-over-year?
- Biodesix, Inc.'s diagnostic tests — revenue increased by 36.6% year-over-year, from $16.32M to $22.29M.
- What is the long-term trend for Biodesix, Inc.'s diagnostic tests — revenue?
- Over 4 years (2021 to 2025), Biodesix, Inc.'s diagnostic tests — revenue has grown at a 12.8% compound annual growth rate (CAGR), from $48.94M to $79.2M.
- What does diagnostic tests — revenue mean?
- This metric represents the total gross revenue generated from the delivery of diagnostic testing services, including clinical trial support and companion diagnostic development. It reflects the market adoption and commercial scale of the company's specialized lung disease diagnostic portfolio. Growth in this figure indicates successful penetration into clinical and biopharmaceutical markets.